Clinical Analysis Of NO And GEMOX Regimen In The Treatment Of Relapsed Or Refractory Non-Hodgkin’s Lymphoma

Objective: To study the clinical efficacy and adverse reaction of the combinationchemotherapy with Vinorelbine(NVB), Oxaliplatin(L-OHP)(NO regimen) and thecombination chemotherapy with Gemcitabine(GEM), Oxaliplatin(L-OHP)(GEMOXregimen)in the treatment of relapsed or refractory non-Hodgkin’s lymphoma(NHL).Methods: The clinical data of one hundred-three patients were analized retrospectively,Fifty-one patients with non-Hodgkin’s lymphoma(NHL) were treated with NO regimenchemotherapy(NVB25mg/m~2, intravenous drip d1、d8, LOHP130mg/m~2, intravenous dripd1); Meanwhile, Fifty-two patients with non-Hodgkin’s lymphoma(NHL) were treatedwith GEMOX regimen chemotherapy (GEM1000mg/m~2, intravenous drip d1、d8, LOHP130mg/m~2, intravenous drip d1), The mean of one chemotherapy period is3weeks, all thepatients are obtained2-6periods’ treatment while Mean is4periods, evaluated forresponse after2cycles at least. Results:(1) The overall response rate(RR) was62.7%,complete response(CR)7.8%, patial response(PR)54.9%. In group NO, The overallresponse rate(RR) was67.3%, complete response(CR)9.6%, patial response(PR)57.7%.In group GEMOX, with no significant difference(P>0.05).(2) The major drug relatedtoxic effects were bone marrow depression and digestive reaction. The thrombocytopeniawas more serious in group GEMOX than in group NO, showing significant difference(P＜0.05).(3) In GEMOX group, the median time to progression of disease was7.58months,In NO group, the median time to progression of disease was7.12months. There was nosignificant difference for PFS between two groups(P>0.05). Conclusion: NO regimenpossesses better short-term efficacy as GEMOX regimen, acceptable toxicity. Thisprotocol is worthy to be warranted as salvage for relapsed or refractory non-Hodgkin’slymphoma.